title: Non-resective ablation and liver transplantation in patients with cirrhosis and hepatocellular carcinoma (HCC): safety and efficacy.
abstract: We investigated the efficacy of nonresective ablation techniques and the tumor-free survival of cirrhotic patients undergoing liver transplantation for hepatocellular carcinoma (HCC). In group 1, 11 HCC patients were treated with these techniques and transplanted. On the waiting list, patients were treated to complete ablation, judged by gadolinium-enhanced MRI and alpha-fetoprotein (AFP) levels. Group 1 was compared with a concurrent group of 10 liver transplant patients (group 2) with incidental HCC (stages T1 three patients, T2 seven patients). The group 1 patients received 36 procedures (4 alcohol ablations, 14 trans -hepatic artery chemo-embolizations, 15 trans -hepatic chemo-infusions, and 3 radio frequency ablations) for treatment of 13 liver masses. Tumor-node-metastasis (TNM) stage was reduced in eight patients (72.7%), unchanged in two patients and increased in one patient before transplantation. The mean waiting time for transplantation was 12.9 7.6 months. Both groups had a tumor-free survival of 100%, at 30 12 months post transplant. On pathology, 54.5% of explanted livers had residual viable HCC after tumor treatment, and 36.4% (4/11) explants had synchronous lesions. Non-resective ablation therapy is safe and effective in reducing the HCC progression in cirrhotic patients awaiting liver transplantation. The cancer-free survival rate in this treatment group is equal to that for incidental T1-T2 HCCs.
authors.affiliation: Division of Transplant Surgery, Department of Radiology, Medical College of Virginia of Virginia Commonwealth University, PO Box 980254, Richmond, VA 23298, USA.
authors.forename: D
authors.initials: D
authors.lastname: Maluf
authors.forename: R A
authors.initials: RA
authors.lastname: Fisher
authors.forename: T
authors.initials: T
authors.lastname: Maroney
authors.forename: A
authors.initials: A
authors.lastname: Cotterell
authors.forename: A
authors.initials: A
authors.lastname: Fulcher
authors.forename: J
authors.initials: J
authors.lastname: Tisnado
authors.forename: M
authors.initials: M
authors.lastname: Contos
authors.forename: V
authors.initials: V
authors.lastname: Luketic
authors.forename: R
authors.initials: R
authors.lastname: Stravitz
authors.forename: M
authors.initials: M
authors.lastname: Shiffman
authors.forename: R
authors.initials: R
authors.lastname: Sterling
authors.forename: M
authors.initials: M
authors.lastname: Posner
mesh_terms: D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000628:therapy*; D018450:Disease Progression; D018572:Disease-Free Survival; D005355:Fibrosis / Q000628:therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D016031:Liver Transplantation / Q000379:methods*; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome